Weigh Risks Versus Benefits in Cancer Patients Needing an Anticoagulant
You'll see clarity about which anticoagulant to use in patients with cancer-associated thromboembolism...due to new Canadian expert guidance.
Dalteparin (Fragmin) and other low-molecular-weight heparins (LMWH) are usually preferred to treat and prevent recurrent venous thromboembolism (VTE) in patients with cancer.
Now more evidence suggests that direct oral anticoagulants (DOACs), such as rivaroxaban (Xarelto), work about as well as LMWH at lowering recurrent VTE risk in cancer patients. Plus DOACs are oral...and cost up to $150/month versus up to $1,800/month for LMWH.